Labcorp has begun rolling out a new blood test that aims to predict the risk of a pregnant person developing preeclampsia, with screening results available as early as the first trimester.

Johnson & Johnson MedTech’s Biosense Webster division presented new clinical data backing up its pulsed field ablation approach for treating atrial fibrillation, which was submitted for FDA review earlier this year.

The Catalogue of Somatic Mutations in Cancer, or COSMIC, has launched its 100th version, parent institution Wellcome Sanger Institute announced May 21. The latest edition of the precision medicine and research resource contains more than 307,000 new gene variants, bringing its total to more than 24 million.

Immunology startup Parallel Bio has released a model of the human immune system that is said to capture the way immunotherapies affect the body more accurately than animals. The so-called “Clinical Trial in a Dish” can purportedly save drug companies up to $1 billion and more than six years of development time.

It’s not a double album release, but it’s a close runner-up: The pivotal SWIFT-1 and SWIFT-2 trials have shown that GSK’s long-acting asthma treatment reduces attacks.

A six-month trial showed that Boston Scientific’s pairing of modular, wireless implants for managing discordant cardiac rhythms—and correcting dangerous ones—could be a successful approach, and the devicemaker has its heart set on an FDA approval for the system in 2025.

Three months after spending $4.3 billion on CymaBay Therapeutics for its primary biliary cholangitis (PBC) med, Gilead Sciences has presented a fresh slice of data as a reminder of seladelpar’s potential while an FDA decision is pending.

Endeavor BioMedicines has linked its Hedgehog inhibitor to improved lung function in a phase 2a idiopathic pulmonary fibrosis (IPF) study, sending a sonic pulse through a sector currently dominated by drugs that only slow the decline of the disease.

The new year burst of biotech IPOs may have sputtered out months ago, but Rapport Therapeutics is a reminder that companies are still willing to test the waters of the public markets.

Bayer’s master plan for its OASIS program is coming together, with the German drugmaker posting phase 3 data that suggest it could challenge Astellas for a recently unlocked menopause market.